^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HLA-C (Major Histocompatibility Complex, Class I, C)

    i
    Other names: HLA-C, Major Histocompatibility Complex, Class I, C, HLA Class I Histocompatibility Antigen, C Alpha Chain, HLA-JY3, D6S204, PSORS1, HLAC, Major Histocompatibility Antigen HLA-C, MHC Class I Antigen Heavy Chain HLA-C, Human Leukocyte Antigen-C Alpha Chain, Psoriasis Susceptibility 1, Human Leukocyte Antigen C, HLA-C Antigen, HLA-Cw, HLC-C, MHC
    Associations

    News

    Trials
    8d
    Revisiting HLA-DQA1*05 in Asian inflammatory bowel disease cohorts: Ethnic variations in genetic susceptibility to immunogenicity. (PubMed, World J Gastroenterol)
    Instead, novel alleles emerge: HLA-C*03:04:01 correlating strongly with anti-infliximab ADAs and HLA-B*15:18:01 with anti-adalimumab ADAs. This letter aimed to contextualize these findings within the broader literature and to lay the ground for further analysis of ethnic variations and the implications for personalized medicine in inflammatory bowel disease. This divergence may suggest how genetic architecture shapes immunogenicity risk across ethnicities.
    Journal
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    11d
    Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance. (PubMed, HLA)
    These findings suggest an important role of HLA class I and II molecules in the genetic susceptibility of MM compared with MGUS, suggesting alterations in peptide-binding capabilities may impair immune recognition of malignant cells. Further studies are needed to validate our findings and elucidate the biological mechanisms.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    11d
    Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer. (PubMed, Cancers (Basel))
    Our study demonstrates that a CLDN18.2-targeting DC vaccine can effectively induce potent antigen-specific CTL responses and elicit significant antitumor immunity in a preclinical model. These findings provide a strong rationale for the clinical development of CLDN18.2-directed DC-based immunotherapy for gastric cancer.
    Journal • IO biomarker
    |
    CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    CLDN18.2 positive
    14d
    DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial (clinicaltrials.gov)
    P1, N=20, Suspended, Fred Hutchinson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    vevoctadekin (ST-067)
    17d
    Interaction between HIV-1 Tat and EBV Zta favours immune escape of B cells by downregulating HLA-ABC expression. (PubMed, Cell Mol Life Sci)
    To conclude, we demonstrated for the first time that HIV-1 Tat and EBV Zta interacted directly in B cells and blood serum; this interaction can be found in people with HIV. This interaction brings about immune evasion of EBV-infected or transformed B cells.
    Journal
    |
    HLA-C (Major Histocompatibility Complex, Class I, C)
    18d
    OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov)
    P2, N=313, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    20d
    Novel association of HLA-DQA1 and HLA-DPB1 alleles with Acute myeloid leukemia susceptibility in (Central Asian) Kazakhstani Population: A Case-Control study. (PubMed, Hum Immunol)
    Class II alleles, especially those within DQA1 and DPB1, are important genetic factors influencing AML susceptibility in the Kazakhstani population.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    21d
    Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies (clinicaltrials.gov)
    P=N/A, N=38, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    23d
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    23d
    Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT (clinicaltrials.gov)
    P1, N=24, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • Orca-T
    27d
    Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2026 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • Zolinza (vorinostat) • cyclosporine
    27d
    Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation (clinicaltrials.gov)
    P2, N=43, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • captisol-enabled melphalan